JP2005508983A5 - - Google Patents

Download PDF

Info

Publication number
JP2005508983A5
JP2005508983A5 JP2003541843A JP2003541843A JP2005508983A5 JP 2005508983 A5 JP2005508983 A5 JP 2005508983A5 JP 2003541843 A JP2003541843 A JP 2003541843A JP 2003541843 A JP2003541843 A JP 2003541843A JP 2005508983 A5 JP2005508983 A5 JP 2005508983A5
Authority
JP
Japan
Prior art keywords
methyl
drug
dione
rheumatic
dmard
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003541843A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508983A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2002/012415 external-priority patent/WO2003039552A1/en
Publication of JP2005508983A publication Critical patent/JP2005508983A/ja
Publication of JP2005508983A5 publication Critical patent/JP2005508983A5/ja
Pending legal-status Critical Current

Links

JP2003541843A 2001-11-09 2002-11-07 Pde4又はpde3/4阻害剤及び抗リウマチ薬の複合薬 Pending JP2005508983A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01000607 2001-11-09
PCT/EP2002/012415 WO2003039552A1 (en) 2001-11-09 2002-11-07 Combination of pde4 or pde3/4 inhibitor and an anti-rheumatic drug

Publications (2)

Publication Number Publication Date
JP2005508983A JP2005508983A (ja) 2005-04-07
JP2005508983A5 true JP2005508983A5 (cg-RX-API-DMAC7.html) 2006-01-05

Family

ID=8176085

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003541843A Pending JP2005508983A (ja) 2001-11-09 2002-11-07 Pde4又はpde3/4阻害剤及び抗リウマチ薬の複合薬

Country Status (6)

Country Link
US (2) US20030092706A1 (cg-RX-API-DMAC7.html)
EP (1) EP1448202A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005508983A (cg-RX-API-DMAC7.html)
AU (1) AU2002300754B2 (cg-RX-API-DMAC7.html)
CA (1) CA2399840C (cg-RX-API-DMAC7.html)
WO (1) WO2003039552A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
DK1511516T3 (da) * 2002-05-28 2009-04-06 Nycomed Gmbh Topisk anvendeligt farmaceutisk præparat
US6727272B1 (en) * 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis
UA82323C2 (uk) * 2002-08-09 2008-04-10 Меда Фарма Гмбх & Ко. Кг Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
ME00524B (me) 2003-03-10 2011-10-10 Astrazeneca Ab Novi postupak za dobijanje roflumilasta
US20070254928A1 (en) * 2004-05-10 2007-11-01 Altana Pharma Ag Use of Roflumilast for the Prophylaxis or Treatment of Emphysema
JPWO2006049215A1 (ja) * 2004-11-02 2008-05-29 大日本住友製薬株式会社 自己免疫疾患を治療するための併用薬
WO2006099256A2 (en) * 2005-03-11 2006-09-21 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
EP1861074B1 (en) * 2005-03-16 2013-04-24 Takeda GmbH Taste masked dosage form containing roflumilast
KR100838702B1 (ko) * 2007-02-08 2008-06-16 한국화학연구원 1-[1-(3,4-디알콕시아릴)-피리딜메틸]-1h-피라졸 화합물의제조방법
US20100203146A1 (en) * 2009-02-09 2010-08-12 Callisto Pharmaceuticals, Inc. Intermittent dosing strategy for treating rheumatoid arthritis
WO2013016718A1 (en) * 2011-07-28 2013-01-31 Cellworks Research India Private Limited Compositions, process of preparation of said compositions and method of treating inflammatory diseases
MA38333A1 (fr) 2013-02-19 2017-02-28 Pfizer Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections
EP3172210B1 (en) 2014-07-24 2020-01-15 Pfizer Inc Pyrazolopyrimidine compounds
DK3177624T3 (da) 2014-08-06 2019-07-01 Pfizer Imidazopyridazinforbindelser
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2231162T3 (es) * 1999-03-10 2005-05-16 Altana Pharma Ag 3-ciclopropilmetoxi-4-difluorometoxi-n-(33,5-dicloropirid-4 il)benzamida en el tratamiento de la esclerosis multiple.

Similar Documents

Publication Publication Date Title
JP2005508983A5 (cg-RX-API-DMAC7.html)
CA2399840A1 (en) Use of roflumilast or pumafentrine in combination with methotrexate for the treatment of arthritic diseases
ES2991544T3 (es) Ketamina para el tratamiento de síntomas relacionados con la menstruación
ES2388425T5 (es) Composición farmacéutica no acuosa para uso dérmico para tratar la psoriasis que comprende una vitamina D, un corticoesteroide y un componente disolvente
ES2363334T3 (es) Combinaciones para el tratamiento de desórdenes inmuno-inflamatorios.
US10456390B2 (en) Combinations comprising MABA compounds and corticosteroids
US20220151955A1 (en) Ketamine for the treatment of postpartum symptoms and disorders
US20160015704A1 (en) Combinations comprising maba compounds and corticosteroids
Elad et al. Budesonide: a novel treatment for oral chronic graft versus host disease
US20090131382A1 (en) Treatment of rheumatoid arthritis using imatinib
JP6502876B2 (ja) 筋ジストロフィーの治療に用いられるジエチル−[6−(4−ヒドロキシカルバモイル−フェニル−カルバモイルオキシ−メチル)−ナフタレン−2−イル−メチル]−アンモニウムクロリド
AU2007201056B2 (en) Treatment of rheumatoid arthritis using imatinib
US20210386716A1 (en) Compositions and methods for blocking the cytokine storm of coronavirus and other medical conditions
AU2003206783A1 (en) Treatment of rheumatoid arthritis using imatinie
JPWO2023006700A5 (cg-RX-API-DMAC7.html)